Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

SBK: Hiroyuki Seki: "we have been out of World Superbike 10 years and we are still learning. The tyres have evolved and we ...

While architectural, museum-worthy nail art is a delight to behold and just as fun to wear, some folks are in the camp of ...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...

Environmental activist Greta Thunberg spawned a new generation of youth eager to combat climate change. Foresight narratives ...

Getting rid of the military’s top lawyers is not exactly a sign that the Trump administration wants to follow the law.

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Dr. Kelly is survived by his son, Ken, four adult grandchildren and 10 great grandchildren. In lieu of flowers, donations may ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...